ALPHAGAN P 0.15 %
BRIMONIDINE TARTRATE : 0.15 % · DIN 02248151 · ABBVIE CORPORATION
Health Canada status: MARKETED
What is ALPHAGAN P?
ALPHAGAN P 0.15 % contains BRIMONIDINE TARTRATE : 0.15 %. It is listed in the Health Canada Drug Product Database under DIN 02248151, held by ABBVIE CORPORATION, supplied as SOLUTION for OPHTHALMIC administration. Health Canada currently lists it as marketed, status dated 28-Nov-2023. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is ALPHAGAN P used for?
Control of intraocular pressure in patients with chronic open-angle glaucoma or ocular hypertension.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02248151 |
|---|---|
| Brand name | ALPHAGAN P |
| Generic / active ingredient | BRIMONIDINE TARTRATE : 0.15 % |
| Manufacturer | ABBVIE CORPORATION |
| Strength | 0.15 % |
| Dosage form | SOLUTION |
| Route of administration | OPHTHALMIC |
| Schedule | Prescription |
| ATC code | S01EA05 BRIMONIDINE |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 28-Nov-2023 |
How is it administered?
One drop in the affected eye(s) three times daily (TID), approximately 8 hours apart. Remove soft contact lenses before use; wait 15 minutes to re-insert.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Store at 15-25°C. (Note: General section 11 mentioned in TOC, but specific range often 15-25°C for this product; text provided ends before section 11 details).
How is it supplied?
5 mL and 10 mL teal, opaque plastic dropper bottles with a purple cap.
Contraindications
Hypersensitivity to drug/ingredients; patients receiving MAO inhibitor therapy; neonates and infants (children under 2 years of age).
Warnings and precautions
For topical ophthalmic use only. May cause fatigue, drowsiness, or blurred vision; use caution when driving. Caution in severe cardiovascular disease or depression.
Is BRIMONIDINE in shortage in Canada?
A Canadian shortage report is on file for this molecule: Active — reported by AA PHARMA INC, last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code S01EA05 BRIMONIDINE. 8 of 17 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| ALPHAGAN | 0.2 % | SOLUTION | ABBVIE CORPORATION | MARKETED | DIN 02236876 |
| BRIMONIDINE P | 0.15 % | SOLUTION | AA PHARMA INC | MARKETED | DIN 02301334 |
| JAMP-BRIMONIDINE | 0.2 % | SOLUTION | JAMP PHARMA CORPORATION | MARKETED | DIN 02449226 |
| LUMIFY | 0.025 % | SOLUTION | BAUSCH & LOMB INC | MARKETED | DIN 02517698 |
| MED-BRIMONIDINE | 0.2 % | SOLUTION | GENERIC MEDICAL PARTNERS INC | MARKETED | DIN 02507811 |
| RIVA-BRIMONIDINE | 0.2 % | SOLUTION | LABORATOIRE RIVA INC. | MARKETED | DIN 02515350 |
| SANDOZ BRIMONIDINE | 0.2 % | SOLUTION | SANDOZ CANADA INCORPORATED | MARKETED | DIN 02305429 |
| APO-BRIMONIDINE | 0.2 % | SOLUTION | APOTEX INC | DORMANT | DIN 02260077 |
| BRIMONIDINE | 0.2 % | SOLUTION | MICRO LABS LIMITED | APPROVED | DIN 02540673 |
| BRIMONIDINE | 0.2 % | SOLUTION | PHARMASCIENCE INC | CANCELLED PRE MARKET | DIN 02249456 |
Who else supplies BRIMONIDINE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. BRIMONIDINE appears in 86 registered pack listings across 12 markets, published on 10 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.